Video Experimental Relacionado
Updated: Sep 9, 2025
11:36
A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
Published on: April 28, 2016
9.4K
Agonistas de los receptores de péptidos similares al glucagón y salud reproductiva: evidencia actual e implicaciones
Jordyn Kettner1, Elizabeth Donnelly2, Marina L Maes3
1Ambulatory Care Clinical Pharmacist, University of Wisconsin Health, Middleton, WI, USA.
Journal of pharmacy practice
|September 4, 2025
Resumen
Los agonistas de los receptores de péptido 1 similares al glucagón (GLP-1RA) ofrecen beneficios para la diabetes y la obesidad, pero requieren atención para la salud reproductiva. Esta revisión pone de relieve los impactos en la anticoncepción, la fertilidad, el embarazo y la lactancia, teniendo en cuenta los datos limitados para las personas embarazadas o lactantes.
Área de la Ciencia:
- Endocrinología y Metabolismo
- Salud Reproductiva
- Farmacología
Sus antecedentes:
- Los agonistas de los receptores de péptido 1 similares al glucagón (GLP-1RA) se utilizan cada vez más para la diabetes tipo 2 y la obesidad.
- Estos agentes proporcionan beneficios metabólicos como la pérdida de peso y el control glucémico.
- Los posibles efectos sobre la salud reproductiva requieren una investigación minuciosa.
Objetivo del estudio:
- Revisar la literatura actual sobre los ARG del GLP-1 en relación con la salud reproductiva.
- Identificar los impactos en la anticoncepción, la fertilidad, el embarazo y la lactancia.
- Informar la toma de decisiones clínicas de los pacientes que utilizan GLP- 1RA.
Principales métodos:
- Revisión sistemática de la literatura de los estudios sobre los ARL-GLP y la salud reproductiva.
- Análisis de los datos relativos a las interacciones farmacológicas con los anticonceptivos orales.
- Evaluación de los efectos sobre la fertilidad, el embarazo y la lactancia.
Principales resultados:
- La tirzepatida puede afectar la absorción de los anticonceptivos orales; otras ARL-GLP muestran una interacción mínima.
- Los ARL-GLP pueden mejorar la fertilidad a través de la pérdida de peso y mejoras metabólicas.
- Existen datos limitados sobre el uso de GLP- 1RA durante el embarazo y la lactancia.
Conclusiones:
- Los GLP-1RA tienen diversas implicaciones en la salud reproductiva, particularmente en lo que respecta a la anticoncepción y la fertilidad.
- Siguen existiendo importantes lagunas de conocimiento con respecto a la seguridad y eficacia en el embarazo y la lactancia.
- La investigación adicional es crucial para guiar la práctica clínica de los usuarios de GLP-1RA.
Videos de Conceptos Relacionados
01:24Glucagon-like Receptor Agonists
415
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
415
01:15Hypoglycemia and Glucagon
334
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
01:06Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255
01:23Dipeptidyl Peptidase 4 Inhibitors
249
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
249